US Broker Ratings

Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling a 49.24% Upside in Biotech

Apogee Therapeutics, Inc. (NASDAQ: APGE), a burgeoning name in the biotechnology sector, is attracting significant investor attention with its promising clinical-stage developments and substantial upside potential. With a market capitalization..

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Evaluating a 27.3% Potential Upside in Healthcare Innovation

Tandem Diabetes Care, Inc. (TNDM) stands at the forefront of medical device innovation, specializing in cutting-edge technology solutions for diabetes management. With a market capitalization of $1.37 billion, Tandem Diabetes..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Exploring a 29% Potential Upside in Biotech Innovation

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a noteworthy player in the biotechnology sector, has been turning investors’ heads with a market capitalization of $2.88 billion and a promising pipeline of innovative..

GeneDx Holdings Corp. (WGS) Investor Outlook: A Promising 62% Upside Potential in the Genomics Sector

GeneDx Holdings Corp. (NASDAQ: WGS) stands as a notable player in the healthcare sector, particularly within the diagnostics and research industry. Headquartered in Stamford, Connecticut, this genomics company specializes in..

Structure Therapeutics Inc. (GPCR) Stock Analysis: Exploring a 20.35% Upside Potential

Structure Therapeutics Inc. (NASDAQ: GPCR) is capturing significant attention in the biotechnology sector with its robust portfolio of novel oral small molecule therapeutics aimed at addressing chronic diseases with unmet..

Dynavax Technologies Corporation (DVAX) Stock Analysis: Exploring a Potential 41.75% Upside

Dynavax Technologies Corporation (NASDAQ: DVAX) is a prominent player in the biotechnology sector, specifically within the specialty and generic drug manufacturing industry. With its headquarters in Emeryville, California, Dynavax focuses..

Astrana Health Inc. (ASTH) Investor Outlook: Unpacking the 35.52% Upside Potential

Astrana Health Inc. (NASDAQ: ASTH), a healthcare management company, has been a subject of interest for investors seeking exposure in the healthcare sector. With its market capitalization standing at $1.37..

Centessa Pharmaceuticals (CNTA) Stock Analysis: Unpacking a 52.47% Upside Potential in Biotech

Centessa Pharmaceuticals plc (NASDAQ: CNTA) is capturing investor attention with its robust growth potential in the biotechnology sector. As a clinical-stage pharmaceutical company, Centessa is focused on discovering, developing, and..

Celldex Therapeutics (CLDX) Investor Outlook: Analysts See Over 100% Upside Potential

For investors seeking promising opportunities in the biotechnology sector, Celldex Therapeutics, Inc. (NASDAQ: CLDX) presents a compelling case. This New Jersey-based biopharmaceutical company is dedicated to developing therapeutic antibodies targeted..

Sotera Health Company (SHC) Stock Analysis: A 9.94% Potential Upside with Robust Revenue Growth

Sotera Health Company (SHC), a key player in the healthcare sector specializing in diagnostics and research, stands out for its strategic positioning and growth potential. With a market capitalization of..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 198% Potential Upside for Investors

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), a biotechnology firm specializing in the development of oral small-molecule and injectable protein therapeutics for rare diseases, is capturing investor attention with a compelling upside..

Immunocore Holdings plc (IMCR) Stock Analysis: Unveiling an 89% Potential Upside in Biotechnology

Immunocore Holdings plc (IMCR), a leading name in the biotechnology sector, is capturing investor attention with its robust pipeline of immunotherapies and a striking potential upside of 89.27%. Headquartered in..

MannKind Corporation (MNKD) Stock Analysis: Why a 72% Upside Could Attract Investors

MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company specializing in therapeutic products for endocrine and orphan lung diseases, has recently captured the attention of investors with its impressive potential upside of..

Acadia Healthcare (ACHC) Stock Analysis: Is a 25% Upside Worth the Risk?

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) is a key player in the healthcare sector, specifically within the medical care facilities industry. Known for its comprehensive range of behavioral healthcare services,..

Select Medical Holdings Corp (SEM) Stock Analysis: A 21% Upside Potential in Healthcare

Select Medical Holdings Corp (NYSE: SEM) is garnering attention from investors as a notable player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization..

Ligand Pharmaceuticals (LGND) Stock Analysis: Unveiling a 22.82% Upside Potential

For investors seeking opportunities in the dynamic biotechnology sector, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presents a compelling case. With a robust pipeline of biopharmaceutical assets, Ligand is a key player..

UFP Technologies, Inc. (UFPT) Stock Analysis: Exploring a 29.79% Upside Potential in the Medical Devices Sector

UFP Technologies, Inc. (NASDAQ: UFPT) is making waves in the medical devices industry with its innovative solutions and robust market presence. Based in Newburyport, Massachusetts, the company is a key..

BGM Group Ltd. (BGM) Stock Analysis: Navigating the Complexities of a Volatile Market with Innovative Healthcare Products

BGM Group Ltd. (BGM) operates in the highly competitive healthcare sector, focusing on the drug manufacturing industry, specializing in both specialty and generic medications. Based in Chengdu, China, BGM has..

CONMED Corporation (CNMD): Stock Analysis Reveals 18% Potential Upside Amidst Healthcare Sector Dynamics

CONMED Corporation (NASDAQ: CNMD), a key player in the healthcare sector, has been making waves with its specialized focus on medical devices designed for surgical procedures. Headquartered in Largo, Florida,..

Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Navigating Biotech Innovation with a 22.59% Upside Potential

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a compelling player in the biotechnology sector, commanding attention with a robust market capitalization of $9.32 billion. Specializing in the development of innovative medicines..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds